US 8101739
Recombinant expression vectors comprising a human codon-optimized marburg virus (MARV) angola glycoprotein gene insert and method of immunization employing said vector
granted A61KA61K2039/5156A61K2039/5254
Quick answer
US patent 8101739 (Recombinant expression vectors comprising a human codon-optimized marburg virus (MARV) angola glycoprotein gene insert and method of immunization employing said vector) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Jan 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America, as represented by the Department of Health and Human Services
- Grant date
- Tue Jan 24 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 8
- CPC classes
- A61K, A61K2039/5156, A61K2039/5254, A61K2039/5256, A61K2039/53